The bifunctional antibody approach continues to pay off for Zenas Biopharma Inc., which banked an upsized $200 million series C preferred stock financing led by SR One along with NEA, Norwest Venture Partners and Delos Capital. Enavate Sciences and Longitude Capital participated significantly as well.
The Australian government is investing AU$1.89 billion (US$1.25 billion) in what it is calling a “once-in-a generation transformation” of health and medical research in Australia with $1.4 billion tagged for new research for the Medical Research Future Fund.
Kymera Therapeutics Inc. has described salts of IL-1 receptor-associated kinase 4 (IRAK-4) degradation inducers and their crystalline forms reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
The Australian government is investing AU$1.89 billion (US$1.25 billion) in what it is calling a “once-in-a generation transformation” of health and medical research in Australia with $1.4 billion tagged for new research for the Medical Research Future Fund.
Chemokine CXCL5 is an inflammatory mediator and a powerful neutrophil chemoattractant, which mainly acts through CXCR2 to produce its biological effects.
Amidst a slew of end-of-week, positive EMA Committee for Medicinal Products for Human Use (CHMP) opinions is Takeda Pharmaceutical Co. Ltd.’s Fruzaqla (fruquintinib). The selective inhibitor of vascular endothelial growth factor receptors-1, -2 and -3 is for adults with previously treated metastatic colorectal cancer.
Amidst a slew of end-of-week, positive EMA Committee for Medicinal Products for Human Use (CHMP) opinions is Takeda Pharmaceutical Co. Ltd.’s Fruzaqla (fruquintinib). The selective inhibitor of vascular endothelial growth factor receptors-1, -2 and -3 is for adults with previously treated metastatic colorectal cancer.
Researchers from Biohaven Pharmaceuticals Inc. presented preclinical data for the first-in-class extracellular bispecific IgG degrader, BHV-1300, being developed for the treatment of neuroinflammatory and autoimmune disease.
Samsung Bioepis Co. Ltd. and Celltrion Inc. are making headway in Europe and U.S. with respective follow-on biologic products, with Samsung Bioepis the latest to gain EMA approval for Pyzchiva, a Stelara (ustekinumab, Janssen Pharmaceuticals Inc.) biosimilar, on April 23.
Evotec SE and Variant Bio Inc. have signed a collaboration agreement to identify treatments for diseases caused by fibrosis. The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.
RSS
